Feb 9 (Reuters) - Indian drugmaker Zydus Lifesciences Ltd ZYDU.NS reported a third-quarter profit above estimates on Monday, underpinned by new drug launches in North America, its biggest market.
The company posted a consolidated profit of 10.42 billion rupees ($115.1 million) for the quarter ended December 31, up from 10.24 billion rupees in the year-ago period.
Analysts, on average, had projected profit to drop to 9.32 billion rupees, as per LSEG-compiled data.
Overall revenue climbed 30.3%, driven by a 16.4% growth in North American sales and nearly a 13% jump in India sales.
KEY CONTEXT
Most Indian generic drugmakers, including Zydus Life, derive a significant portion of their revenue from the U.S. market but have been grappling with weak pricing due to intense competition.
New drug launches, particularly in Zydus' specialty portfolio, have lifted growth in the United States since early 2025. The company launched four more products in the reported quarter.
Meanwhile, Zydus' peers Cipla CIPL.NS and Dr Reddy's REDY.NS reported subdued U.S. sales during the quarter.
PEER COMPARISON
Estimates (next 12 months)
Analysts' sentiment
RIC
EV/EBITDA
Revenue growth (%)
Profit growth (%)
Mean rating*
# of analysts
Stock to price target**
Div yield (%)
Zydus Lifesciences Ltd
ZYDU.NS
14.34
7.15
-10.25
Hold
29
0.88
1.24
Alembic Pharmaceuticals Ltd
ALEM.NS
12.31
10.68
22.55
Buy
11
0.81
1.38
Dr Reddy's Laboratories Ltd
REDY.NS
13.22
3.29
-10.23
Hold
39
0.93
0.64
Cipla Ltd
CIPL.NS
15.09
7.85
0.62
Hold
37
0.91
0.98
* The mean of analyst ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT
OCTOBER TO DECEMBER STOCK PERFORMANCE
-- All data from LSEG
-- $1 = 90.5590 Indian rupees
ZYDU v Peers https://tmsnrt.rs/3M1Ky7M
(Reporting by Kashish Tandon in Bengaluru; Editing by Sherry Jacob-Phillips)
((Kashish.Tandon@thomsonreuters.com; 8800437922;))